Erlotinib has better efficacy than gefitinib in adenocarcinoma patients without EGFR-activating mutations, but similar efficacy in patients with EGFR-activating mutations

DM ParkinF BrayJ FerlayGlobal cancer statisticsCA Cancer J Clin5574108200510.3322/canjclin.55.2.74

N ThatcherA ChangP ParikhGefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)Lancet36615271537200510.1016/S0140-6736(05)67625-8

FA ShepherdPJ RodriguesT CiuleanuErlotinib in previously treated non-small-cell lung cancerN Engl J Med353123132200510.1056/NEJMoa05075316014882

A ChangP ParikhS ThongprasertGefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: Subset analysis from the ISEL studyJ Thorac Oncol1847855200610.1097/01243894-200610000-0001417409969

ES KimV HirschT MokGefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trialLancet37218091818200810.1016/S0140-6736(08)61758-419027483

TS MokY-L WuS ThongprasertGefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaN Engl J Med361947957200910.1056/NEJMoa081069919692680

R RosellT MoranC QueraltScreening for epidermal growth factor receptor mutations in lung cancerN Engl J Med361958967200910.1056/NEJMoa090455419692684

C ZhouYL WuG ChenEfficacy results from the randomized phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM), in Chinese advanced non-small-cell lung cancer (NSCLC) patients (PTS) with EGFR activating mutationsAnn Oncol21Suppl 8LBA132010

YM ChenJ Whang-PengCM ChenReview of first-line systemic therapy for metastatic non-small cell lung cancerJ Exp Clin Med3116120201110.1016/j.jecm.2011.04.008

PA JanneBE JohnsonEffect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitorsClin Cancer Res12Suppl 1444164420200610.1158/1078-0432.CCR-06-0555

T KosakaY YatabeH EndohMutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implicationsCancer Res6489198923200410.1158/0008-5472.CAN-04-2818

H ShigematsuL LinT TakahashiClinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancersJ Natl Cancer Inst97339346200510.1093/jnci/dji05515741570

J BaselgaD RischinM RansonPhase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor typesJ Clin Oncol2042924302200210.1200/JCO.2002.03.100

RS HerbstAM MaddoxML RothenbergSelective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trialJ Clin Oncol2038153825200210.1200/JCO.2002.03.038

M HidalgoLL SiuJ NemunaitisPhase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignanciesJ Clin Oncol1932673279200111432895

SV SharmaDW BellJ SettlemanEGFR growth factor mutations in lung cancerNat Rev Cancer7169181200710.1038/nrc2088

WC FanCJ YuCM TsaiDifferent efficacies of erlotinib and gefitinib in Taiwanese patients with advanced non-small cell lung cancer: a retrospective multi-center studyJ Thor Oncol6148155201110.1097/JTO.0b013e3181f77b2721107294

T CiuleanuL StelmakhS CicenasErlotinib versus docetaxel or pemetrexed as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC) and poor prognosis: efficacy and safety results from the phase III TITAN studyChicago Multidisciplinary Symposium in Thoracic Oncol: LBOA52010

L VamvakasS AgelakiNK KentepozidisPemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small cell lung cancer (NSCLC): results of a randomized phase III Hellenic Oncology Research Group trialProc ASCO2875192010

P TherasseSG ArbuckEA EisenhauerNew guidelines to evaluate the response to treatment in solid tumors. European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of CanadaJ Natl Cancer Inst92205216200010.1093/jnci/92.3.205

TJ LynchDW BellR SordellaActivating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinibN Engl J Med35021292139200410.1056/NEJMoa04093815118073

JG PaezPA JanneJC LeeEGFR mutations in lung cancer: correlation with clinical response to gefitinib therapyScience30414971500200410.1126/science.109931415118125

JD MoyerEG BarbacciKK IwataInduction of apoptosis and cell cycle arrest by OSI-774, an inhibitor of epidermal growth factor receptor tyrosine kinaseCancer Res574838484819979354447

VA PolackDM SavageDA BakerInhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinoma with OSI-774: dynamics of receptor inhibition in situ and antitumor effects in athymic miceJ Pharmacol Exp Ther2917397481999

BC ChoCK ImMS ParkPhase II study of erlotinib in advanced non-small cell lung cancer after failure of gefitinibJ Clin Oncol2525282533200710.1200/JCO.2006.10.416617577030

SV SharmaDW BellJ SettlemanEpidermal growth factor receptor mutations in lung cancerNat Rev Cancer7169181200710.1038/nrc208817318210

J GandhiJ ZhangY XieAlterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell linesPLoS One4e4576200910.1371/journal.pone.000457619238210

CQ ZhuGC SantosK DingRole of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21J Clin Oncol2642684275200810.1200/JCO.2007.14.892418626007

F CappuzzoT CiuleanuL StelmakhErlotinib as maintenance treatment in advanced non-small cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 studyLancet Oncol11521529201010.1016/S1470-2045(10)70112-120493771